Diagnosis and
Management of Hepatocellular
Carcinoma: 2009 Update
Target Audience
This activity has
been designed to meet the
educational needs of hepatologists,
gastroenterologists, physician
assistants, and nurse practitioners
involved in the management of
chronic liver disease.
Goal Statement
To provide important
clinical data on the management of
hepatocellular carcinoma (HCC)
Educational
Objectives
Upon completion of
this activity, participants should
be better able to:
Credit Designation
• Review the epidemiology and
etiology of HCC
1.0 AMA PRA Category
1 Credit(s)™
• Describe the latest treatment
advances
• Discuss the latest treatment
algorithms for the management of HCC
Please see page 1 of
the monograph for full accreditation
statement.
Jointly sponsored by
Purdue University School of
Pharmacy and the Chronic
Liver Disease Foundation.
This educational material
was supported by grants from
Bayer Healthcare LLC and
Onyx Pharmaceuticals.
Hepatocellular carcinoma in patients with cryptogenic cirrhosis
Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group. Clinical Gastroenterol Hepatol. 2009;7:580-5.
Sorafenib in Advanced Hepatocellular Carcinoma
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, de Oliveira A, Santoro A, Raoul J, Former A, Schwartz M, Porta C, Zeuzem, Bolondi L, Greten T, Galle P, Seitz J, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, and Bruix J for the SHARP Investigators Study Group. N Engl J Med 2008;359:378-90.